Evidence mapPaperPMID 39755997Full record

ArticleHepatology international2025

Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association study.

Shao-Wen Wang, Ching Wang, Yu-Ming Cheng, Chun-Yi Chen, Tsung-Han Hsieh, Chia-Chi Wang, Jia-Horng Kao

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Biomolecules & biomedicine · 2025
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shao-Wen WangDepartment of Education, Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan.
Ching WangNational Yang Ming Chiao Tung University, Hsinchu City, Taiwan.
Yu-Ming ChengDepartment of Gastroenterology and Hepatology, Tung's Taichung MetroHarbor Hospital, Taichung, Taiwan.
Chun-Yi ChenDepartment of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
Tsung-Han HsiehDepartment of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
Chia-Chi WangDepartment of Gastroenterology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and School of Medicine, Tzu Chi University, 289 Jianguo Rd., Xindian Area, New Taipei City, 23142, Taiwan. wangchiachi888@gmail.com.ORCID http://orcid.org/0000-0002-0827-4503
Jia-Horng KaoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Funding

Buddhist Tzu Chi Hospital TCMF-A110-05(113)Taipei Tzu Chi Hospital TCRD-TPE-111-9
6 · The paper itself

Abstract

background/purposeAlthough metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed to replace the diagnosis of non-alcoholic fatty liver disease (NAFLD) with new diagnostic criteria since 2023, the genetic predisposition of MASLD remains to be explored.

methodsParticipants with data of genome-wide association studies (GWAS) in the Taiwan Biobank database were collected. Patients with missing data, positive for HBsAg, anti-HCV, and alcohol drinking history were excluded. MASLD was defined if having hepatic steatosis on ultrasound, plus at least one of cardiometabolic criteria. The Taiwan biobank used two genetic chips during the period of data collection: Taiwan biobank version 1 (TWBv1) as the initial chip and TWBv2 specifically designed for the Taiwanese population. TWBv2 was used as test group and TWBv1 as validation group. NAFLD fibrosis score (NFS) was used to assess the degree of liver fibrosis, and carotid plaques on duplex ultrasound were employed for the diagnosis of atherosclerosis.

resultsIn a total of 16,407 (mean age 55.35 ± 10.41; 29.6% males) participants, 6722 (41.0%) had MASLD. Eleven single-nucleotide polymorphisms (SNP) were identified to be associated with MASLD. Their functions were exonic in two and intronic in nine. They were related to the PNALA3, and SAMM50 genes located on chromosome 22. The linkage disequilibrium showed a high correlation with each other. Four SNPs of PNALA3 and SAMM50 genes had increased risk of MASLD and higher levels of AST/ALT. In addition, there was no association of these two genes with glucose metabolism, but better lipid profiles in SAMM50.

conclusionsThis large GWAS study indicates that eleven SNPs of PNPLA3 and SAMM50 genes predispose the development of MASLD in Taiwanese population.

Indexed as

Fatty LiverGenetic Predisposition to DiseaseNon-alcoholic Fatty Liver DiseaseAcyltransferasesAdultAgedFemaleGenome-Wide Association StudyHumansMaleMiddle AgedPhospholipases A2, Calcium-IndependentPolymorphism, Single NucleotideTaiwanAcyltransferasesPhospholipases A2, Calcium-IndependentPNPLA3 protein, humanGenome-wide association studiesMetabolic associated steatotic liver diseasePNPLA3SAMM50Single-nucleotide polymorphismTaiwan biobank

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.